Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Rocuronium Bromide Injection Obtains Drug Registration Certificate.
Jianniu Corporation (603707.SH) announced that the company recently received the approval for Rocuronium Bromide issued by the National Medical Products Administration.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company has recently received the drug registration certificate for Rocuronium Bromide Injection 5ml:50mg and 10ml:100mg issued by the National Medical Products Administration.
Rocuronium Bromide Injection is used as an adjuvant for general anesthesia, to facilitate tracheal intubation during routine induction of anesthesia, and to maintain neuromuscular blockade of skeletal muscles during surgery.
Related Articles
WINOX(06838) announces annual performance with a net loss of HKD 61.47 million, a year-on-year increase of 202.41%.
FRONTAGE (01521) released its annual performance with a net profit attributable to shareholders of $6.793 million, a year-on-year increase of 758.8%.
WANGUO GOLD GP (03939) spent about HKD 816,500 to buy back 65,500 shares on March 30th.
WINOX(06838) announces annual performance with a net loss of HKD 61.47 million, a year-on-year increase of 202.41%.
FRONTAGE (01521) released its annual performance with a net profit attributable to shareholders of $6.793 million, a year-on-year increase of 758.8%.
WANGUO GOLD GP (03939) spent about HKD 816,500 to buy back 65,500 shares on March 30th.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
